Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) produced a 65.27% rally since recording the worst price of $6.22. Thanks to the latest -3.38% decrease, it now trades at $10.28. Throughout the trading on 3/14/2019, the share price floated between $10.27 and $10.755. This company shares are 167.51% off its target price of $27.5 and the current market capitalization stands at $1.12B. The recent change has given its price a -4.78% deficit over SMA 50 and -59.35% deficit over its 52-week high. The stock witnessed -11.38% declines, -19.69% declines and -51.33% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SPPI’s volatility during a week at 4.49% and during a month it has been found around 4.76%.Spectrum Pharmaceuticals, Inc. (SPPI) Top Holders
Institutional investors currently hold around $920 million or 80.1% in SPPI stock. Look at its top three institutional owners: Blackrock Inc. owns $175.92 million in Spectrum Pharmaceuticals, Inc., which represents roughly 15.71% of the company’s market cap and approximately 19.12% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 11,112,007 shares of the stock are valued at $118.23 million. The third largest holder is Primecap Management Co/Ca/, which currently holds $117.4 million worth of this stock and that ownership represents nearly 10.48% of its market capitalization.Spectrum Pharmaceuticals, Inc. 13F Filings
At the end of December reporting period, 87 institutional holders increased their position in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) by some 9,411,435 shares, 90 decreased positions by 11,794,357 and 31 held positions by 65,305,878. That puts total institutional holdings at 86,511,670 shares, according to SEC filings. The stock grabbed 20 new institutional investments totaling 2,608,193 shares while 34 institutional investors sold out their entire positions totaling 1,950,984 shares.Spectrum Pharmaceuticals, Inc. (SPPI) Analyst Guide
Several analysts have released their opinion on Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation [T1].